Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-11

Study Completion Date

2017-02-27

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is conducted in two phases. The Dose-finding Lead-in Phase, Part A, will evaluate the safety and determine the maximum tolerated dose (MTD) of momelotinib (MMB) when combined with trametinib. Once the MTD of momelotinib (MMB) is determined, the study will proceed to the Dose-finding Lead-in Phase, Part B, to determine the MTD of trametinib. After the MTD is established, the study may proceed to an expansion phase to determine the efficacy, safety, and tolerability of MMB combined with trametinib at the MTD in participants with kirsten rat sarcoma viral oncogene homolog (KRAS) mutated metastatic non-small cell lung cancer (NSCLC). Each treatment cycle will consist of 28 days and treatment will continue in the absence of disease progression, unacceptable toxicity, consent withdrawal, or participant's refusal of treatment.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib

NCT02538627

Colorectal Cancer Non-small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck

TERMINATED PHASE1

Temozolomide in Treating Patients With Metastatic Non-small Cell Lung Cancer

NCT00006877

Lung Cancer

COMPLETED PHASE2

Temozolomide in Patients With Progressive or Recurrent Non-small Cell Lung Cancer

NCT00003062

Lung Cancer

COMPLETED PHASE2

Biomarker Directed Trial of Temozolomide and Stenoparib in Relapsed SCLC

NCT06681220

Relapsed Small Cell Lung Cancer Recurrent Small Cell Lung Cancer

NOT_YET_RECRUITING PHASE1/PHASE2

Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)

NCT05638295

Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm

RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Momelotinib (MMB) dose escalation

Participants will receive momelotinib (MMB) plus trametinib. Momelotinib (MMB) dose will increase to find the MTD.

Group Type EXPERIMENTAL

Momelotinib (MMB)

Intervention Type DRUG

Momelotinib (MMB) tablet(s) administered orally once or twice daily

Trametinib

Intervention Type DRUG

Trametinib tablet administered orally once daily

Trametinib dose escalation

Participants will receive momelotinib (MMB) plus trametinib. Trametinib dose will increase to find the MTD.

Group Type EXPERIMENTAL

Momelotinib (MMB)

Intervention Type DRUG

Momelotinib (MMB) tablet(s) administered orally once or twice daily

Trametinib

Intervention Type DRUG

Trametinib tablet administered orally once daily

Momelotinib (MMB)+trametinib

Expansion Phase: participants will receive momelotinib (MMB) plus trametinib for the duration of the study.

Group Type EXPERIMENTAL

Momelotinib (MMB)

Intervention Type DRUG

Momelotinib (MMB) tablet(s) administered orally once or twice daily

Trametinib

Intervention Type DRUG

Trametinib tablet administered orally once daily

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Momelotinib (MMB)

Momelotinib (MMB) tablet(s) administered orally once or twice daily

Intervention Type DRUG

Trametinib

Trametinib tablet administered orally once daily

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

GS-0387 CYT387

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Individuals with KRAS-mutated metastatic or recurrent non-small cell lung cancer
* Radiologic documentation of disease progression
* Measurable disease per RECIST v1.1
* Adequate organ function defined as follows:

* Hepatic: Total conjugated bilirubin ≤ 1.25 x upper limit of normal (ULN); aspartate transaminase (AST) and alanine transaminase (ALT) \< 3 x upper limit of normal (ULN) or \< 5 x ULN in the setting of liver metastases
* Hematological: Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L, platelet ≥ 100 x 10\^9/L, hemoglobin ≥ 9 g/dL

* Renal: Serum creatinine \< 1.5 x ULN OR calculated creatinine clearance (CLcr) ≥ 60 ml/min
* Adequate left ventricular ejection fraction (LVEF) ≥ 50%
* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
* Negative serum pregnancy test for females

Exclusion Criteria

* Less than or equal to 3 weeks since receiving treatment with biologic, small molecule, chemotherapy or other agent for non-small cell lung cancer and 28 days since any prior immunotherapy (such as nivolumab)
* History of a concurrent or second malignancy, except for specified exceptions in the protocol or any other cancer that has been in complete remission for ≥ 5 years
* Known positive status for human immunodeficiency virus (HIV)
* Chronic active or acute viral hepatitis A, B, or C infection or hepatitis B or C carrier
* Presence of ≥ Grade 2 peripheral neuropathy
* Brain metastases, or spinal cord compression. Individuals with brain metastases are allowed if they have been treated with irradiation or surgery, are clinically stable without steroid treatment. Individuals with documented leptomeningeal disease are not eligible
* A history of uveitis and/or scleritis
* Retinal pathology beyond normal age-related processes
* Evidence of a retinal vein occlusion on ophthalmological exam or a history of retinal vein occlusion
* History of newly diagnosed or uncontrolled glaucoma/intraocular pressure \> 21 mm Hg as measured by tonography
* Use of daily and/or chronic oral or ocular steroids. Individuals must be off daily steroids for at least 3 weeks prior to enrolling into the trial
* History of interstitial pneumonitis
* History of long QT syndrome or whose corrected QT interval (QTc) measured (Fridericia method) at screening is prolonged (\> 480 ms for males and females)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No